Covered Companies: CNS Pharmaceuticals
Most Recent Event
What This Means
September 01, 2026
Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provides an update on its business development strategy as part of its broader transformation as the Company works to establish a pipeline focused on oncology or neurology with best in class potential.
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases.
NASDAQ: CNSP
About
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.
Past Events
“Why Now” On-Demand Conference
August 27, 2026
On-demand video series giving investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching today.
What This Means
June 8, 2026
Steve O’Loughlin, Chief Financial Officer of CNS
Pharmaceuticals, discusses the Company’s recently completed oversubscribed $22.5 million financing, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation.
CEO Connect
May 20, 2026
Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company’s recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.